A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and its Anti-tumour Effect in Adult Patients with CD44v6 Expressing Solid Tumours

2023-508126-95-00 Protocol AKIR001 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 10 Feb 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol AKIR001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 30
Countries 1
Sites 1

The target population of the trial consists of patients with locally advanced irresectable or metastatic solid malignancies, such as advanced thyroid cancer, squamous cell carcinoma originating from head and neck region, vulvar or cervix squamous cell carcinoma, and non-small cell lung cancer.

Key facts

Sponsor
Karolinska University Hospital
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
10 Feb 2025 → ongoing
Decision date (initial)
2024-09-12
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

The target population of the trial consists of patients with locally advanced irresectable or metastatic solid malignancies, such as advanced thyroid cancer, squamous cell carcinoma originating from head and neck region, vulvar or cervix squamous cell carcinoma, and non-small cell lung cancer.

VersionLevelCodeTermSystem organ class
21.1 PT 10041848 Squamous cell carcinoma of the cervix 100000004864
21.1 PT 10002240 Anaplastic thyroid cancer 100000004864
26.1 PT 10060121 Squamous cell carcinoma of head and neck 100000004864
21.1 PT 10071030 Thyroid cancer stage IV 100000004864
26.1 PT 10041875 Squamous cell carcinoma of the vulva 100000004864
21.1 PT 10061873 Non-small cell lung cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Karolinska University Hospital

Sponsor organisation
Karolinska University Hospital
Address
Eugeniavagen 3
City
Solna
Postcode
171 64
Country
Sweden

Scientific contact point

Organisation
Karolinska University Hospital
Contact name
Robert Bränström

Public contact point

Organisation
Karolinska University Hospital
Contact name
Robert Bränström

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Sweden Ongoing, recruiting 30 1
Rest of world 0

Investigational sites

Sweden

1 site · Ongoing, recruiting
Karolinska University Hospital
Center for Clinical Cancer Studies, Eugeniavagen 3, 171 64, Solna

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Sweden 2025-02-10 2025-02-27

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-06-25 Sweden Acceptable
2024-09-09
2024-09-12
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-18 Sweden Acceptable
2025-01-09
2025-01-20
3 SUBSTANTIAL MODIFICATION SM-3 2026-01-15 Sweden Acceptable
2026-03-03
2026-03-06